

Secondary Prevention of Stroke Order and Documentation Template

The following actions are based on the 2014 Update of Canadian Stroke Best Practice Recommendations for Secondary Prevention of Stroke (www.strokebestpractices.ca). This document is intended to be used as a template to ensure alignment of organization specific care with the Stroke Best Practices for secondary stroke prevention. Institutional specific standards for routine precautions, assessment and care should be followed.

Patients with stroke and TIA who present to an ambulatory setting or a hospital should undergo clinical evaluation by a healthcare professional with expertise in stroke care to determine risk for recurrent stroke and initiate appropriate investigations and management strategies (CSBPR Secondary Prevention of Stroke, Recommendation 1).

Date	Time				
Setting for Assessment:					
☐ Emergency Department	☐ Stroke Prevention Clinic				
☐ Primary Care Office ☐	Other Ambulatory Setting				
I. Initial Risk Stratifica	tion and Management				
Stroke Symptom History a	and Presentation				
Record Onset of Stroke Syr	nptoms (or last time seen as norma	al)			
.	ime since onset of stroke symptom al Risk Stratification and Managem	ns and clinical presentation (Refer to ent)			
☐ Conduct history and phys	sical examination to establish diagr	nosis of TIA/non-disabling stroke			
Stroke Severity and Focal	Deficits				
☐ Complete baseline asses	sment with standardized stroke sc	ale			
☐ National Institute of	of Health Stroke Scale (NIHSS)	Record baseline Score:			
or ☐ Canadian Neurolo	or □ Canadian Neurologic Scale (CNS) Record baseline Score:				
or □ Neurovital signs					

<u>Investigations</u> (refer to Recommendation 1.2, CSBPR Secondary Prevention of Stroke)

Vital Signs and Asses	ssment	
☐ Record baseline vita	ıl signs	
Temperature	_°C Heart Rate/min.	
Blood Pressure	/mmHg Respiratory Rate	
☐ SpO₂ via pulse oxim	etry %	O ₂ at %
□Actual Weight	kg or □ Estimated Weight _	kg
☐ Height	cm Body Mass Index (BMI) calcula	ated kg/m ²
Neuroimaging		
☐ CT Angiography	or ☐ MR Angiograpy	
Urgency: ☐ STAT	☐ Same-day ☐ Within 24 hours	☐ Within 2 weeks ☐ Within 1 month
☐ Scan scheduled	Date:	Time:
☐ Scan completed	Date:	Time:
☐ Other Non-invasive	Vascular Imaging (intra- and extracranial	vasculature)
☐ Carotid Ultrasour	nd □ Scheduled (date)	_ □ Completed (date)
Neurovascular Interversion ☐ Referral to neurovas		Date:
	pmy scheduled Date:	
Cardiac	,	
☐ Complete 12 lead E	CG	
Presence of Atrial Fibri		
□ No	nauon.	
	ECC monitoring	
☐ Order prolonged	•	onitoring
☐ Holter Monitor	☐ Loop Recorder ☐ Event Mo	•
☐ Yes	nitoring	
	nbotic administration recommendations b	polow (page 5)
- Veiei (0 Allii(III0)	moduc administration recommendations b	below (page 3)

Recommended Laboratory Investigations for Patients with Acute Stroke or TIA

(Refer to Box One, CSBPR Secondary Prevention of Stroke)

Order initial Laboratory Investigations on arrival	to the emergency department
□ CBC	☐ capillary glucose
□ Electrolytes	☐ blood and/or urine drug screen (if clinically
□ PTT	indicated)
□ INR	urine or serum β HCG (if female of childbearing
□ creatinine	age)
□ e-GFR	☐ cross and type may be considered
Order additional Laboratory Investigations to be (should only be completed on appropriate patien	
☐ fasting lipid profile	☐ HIV, syphilis serology (if clinically indicated)
☐ Hemoglobin A1c	☐ blood cultures x 3 (per individual institutional
☐ fasting glucose	protocol
□ ALT	
Consider ordering Immunological Tests (to be co only on appropriate patients when clinically indicated	·
\square erythrocyte sedimentation rate (ESR)	□ C3/C4
☐ C-reactive protein (CRP)	□ c- and p-ANCA
□ antinuclear antibody (ANA)	☐ ENA (anti SSA, SSB, anti-Smith, andti-DS DNA)
Consider ordering Coagulopathy Screen (to be coonly on appropriate patients when clinically indicated	
☐ anticardiolipin (Antiphospholipd) antibody	☐ Sickle cell screen
□ lupus anticoagulant	☐ Anti-beta2-glycoprotein type 1
Special considerations for young adults, children identified etiology and clinical suspicion of rarer	
□ consider LP for CSF analysis (cell count and difference of the count and difference	
possibly cytology/flow cytometry if CNS lymphom	•
☐ Further genetic tests – CADASIL, Fabry's, MELAS	
☐ Further blood tests – Lipoprotein (a), Homocystein	
☐ Brain biopsy (if vasculitis of the central nervous sy	
	s (CVST), consider additional coagulopathy rothrombin gene mutation, factor V Leiden mutation. se of stroke (i.e. after three months or so, or as per

Record Type of Stroke		
☐ Acute Ischemic Stroke	☐ Transient Ischemic Attack	☐ Venous Sinus Thrombosis
☐ Subarachnoid Hemorrhage	☐ Intracerebral Hemorrhage	
☐ Other		
Consults		
Physicians		
	Name	Appointment Date
☐ Stroke Prevention Clinic		
☐ Stroke Neurologist		
☐ Neurosurgeon		
☐ Vascular Surgeon		
☐ Other		
☐ Other		
Interdisciplinary Stroke Team Me	embers/External Services	
	Name	Appointment Date
☐ Pharmacist		
☐ Physiotherapist		
☐ Occupational Therapist		
☐ Occupational Therapist ☐ Speech Language Pathologist		
☐ Speech Language Pathologist		
☐ Speech Language Pathologist☐ Social Worker		
☐ Speech Language Pathologist ☐ Social Worker ☐ Registered Dietician		
□ Speech Language Pathologist □ Social Worker □ Registered Dietician □ Psychiatrist □ Psychologist/		
□ Speech Language Pathologist □ Social Worker □ Registered Dietician □ Psychiatrist □ Psychologist/ Neuropsychologist		
□ Speech Language Pathologist □ Social Worker □ Registered Dietician □ Psychiatrist □ Psychologist/ Neuropsychologist □ Physiatrist		

II. Immediate Secondary Prevention Strategies

Antiplatelet Therapy in Ischemic Stroke and TIA Start antiplatelet therapy immediately after ruling out intracranial hemorrhage (Refer to recommendation 6, CSBPR Secondary Prevention of Stroke):

,,					
Administer one of:					
 □ ECASA 160 – 325 mg load, followed by 81 mg daily, or □ Clopidogrel 300 mg load, followed by 75 mg daily, or 					
□ ECASA 160 – 325	mg load, followed	d by ASA 25 mg/d	ipyridamole 200 r	ng twice daily	
☐ Drug administered:					
(drug)	(dose)	(route)	(date)	(time)	
Note: Short-term concu. an increased risk of blee there is an alternate indi	eding; however, lon	ger-term use is not	recommended for s	econdary stroke prev	vention, unless
Antithrombotic for A	trial Fibrillation	for Individuals w	vith Stroke		
Patients with TIA or is the following (Refer to for the Prevention of S	CSBPR Second	ary Prevention of			
Order one of:					
☐ Apixaban m	g PO BID, or				
☐ Dabigitran m	ng PO BID, <i>or</i>				
☐ Rivaroxiban	mg PO once dail	y,			
☐ Edoxaban (when a	vailable for use ir	n Canada) ı	mg daily, <i>or</i>		
☐ Warfarin loading do	ose of mg	PO daily for	_ days		
	R on e dose: Warfarin	(target l mg daily	INR 2.5; range 2-	3)	
☐ for DOACs, monito	•	tatus at least ann	ually, or following	a change in health	ı status
☐ Antithrombotic adm	ninistered:				
(drug)	(dose)	(route)	(date)	(time)	

Note: Concomitant antiplatelet therapy with anticoagulation is not recommended in patients with AF unless there is a specific medical indication (Recommendation 7.3, iii).

III. Strategies for Risk Factor and Symptom Management

☐ Refer to CSBPR Post-Stroke	e Checklist (appended to this document) for additional information
☐ Review CSBPR Post-Stroke Clinic visits	Checklist with the patient at initial and all follow-up Stroke Prevention
☐ Assess and TREAT all vasc lifestyle practices, including	ular risk factors, additional patient-specific risk factors and sub-optimal
	ercise, weight, alcohol intake, use of oral contraceptives and hormone and recreational drug use
□ Provide referrals and links to supportive services	appropriate community-based lifestyle modification programs and
Program/service:	
Program/service:	
Program/service:	
Program/service:	
Blood Pressure Management	Ł
☐ Baseline blood pressure	mm Hg
of Stroke, and prescribe trea	a.0, Blood Pressure and Stroke Prevention, CSBPR Secondary Prevention atment according to current CHEP guidelines. mmHg Target diastolic:mmHg
•	niming harget diastolicnimingniming
	Dose, Route, Frequency:
□ ivieuication.	Dose, Route, Frequency:
Lipid Management	
☐ Refer to Recommendation 4	.0, Lipid Management, CSBPR Secondary Prevention of Stroke
☐ Medication:	Dose, Route, Frequency:
☐ Medication:	Dose, Route, Frequency:
Diabetes Management	
☐ Refer to Recommendation 5	.0, Diabetes and Stroke, CSBPR Secondary Prevention of Stroke
☐ Medication:	Dose, Route, Frequency:
☐ Medication:	Dose, Route, Frequency:

Pain Management	
☐ Acetaminophen	mg PO/NG/PR q4h PRN/Scheduled (maximum daily dose mg)
☐ Medication:	Dose, Route, Frequency:
☐ Medication:	Dose, Route, Frequency:
☐ Non-pharmacologica	I management:
Nausea Management	
☐ Dimenhydrinate 25 -	50 mg PO/NG/IV/PR q4h PRN (use lowest possible for effect for elderly/frail)
☐ Dimenhydrinate 12.5	- 25 mg PO/NG/IV/PR/IM q4h PRN (use lowest possible for effect for elderly/frail
☐ Medication:	Dose, Route, Frequency:
Smoking Cessation	
$\hfill\square$ Identify, assess and	document smoking status:
	dation 9.0, Smoking Cessation for Individuals with Stroke, and Table 9: or Smoking Cessation in Patients with Stroke and TIA, CSBPR Secondary e.
☐ Referral to Smoking	Cessation Program/Specialist: (Name)
☐ Appointment sch	eduled: (date/time)
☐ Order smoking cessa	ation medication*:
Dose, Route, Freque	ncy:
Assessment and Man	agement of Depression, Anxiety, Cognitive Changes and Fatigue
Patients and family me	mbers (especially primary caregivers) should be screened
☐ Cognitive evaluation	(executive function, IADLs, memory)
☐ Depression screenin	g □ Caregiver depression screening
☐ Referral for compreh	ensive assessments (specify):
☐ Appointment sch	eduled: (name)
Date/time:	
☐ Appointment sch	eduled: (name)
Date/time:	
☐ Assess for post-strok	ce fatigue
☐ Provide informatio	n and education regarding post-stroke fatigue
☐ Intervention(s) rec	ommended:

CSBPR Secondary Prevention of Stroke) ☐ Screen for sleep apnea symptoms ☐ Referral to sleep specialist if initial screening is suggestive of sleep apnea symptoms ☐ Appointment scheduled: (name) _____ Date/time: ☐ Additional recommendations _____ **Functional Assessment and Management** ☐ Fitness to drive assessed ☐ Mobility assessment □ Precautions: ☐ Need for assistive device: ☐ Assessment for incontinence ☐ Assessment for spasticity ☐ Assessment of speech and communication ☐ Referrals: □ Appointment scheduled: (name)_____ Purpose: Date/time: ☐ Appointment scheduled: (name)______Purpose: _____ Date/time: **Other Medications** ☐ Medication: Dose, Route, Frequency: ☐ Medication: ______ Dose, Route, Frequency: _____ ☐ Medication: ______ Dose, Route, Frequency: _____ ☐ Medication: ______ Dose, Route, Frequency: _____ **Discharge/Transition Plan** ☐ Provide patient and family education and skills training as required regarding (initial when completed): ____ Diagnosis Stroke signs and symptoms and appropriate actions to take __ Contact numbers for EMS, neurologist, stroke team, other healthcare professionals ____ Risk Factor modification – assist with development/update of an individualized plan ____ Activity levels, activities of daily living Safety and avoidance of falls and injury ____ Rehabilitation

Sleep Apnea Assessment and Management (Refer to Recommendation 10.0, Sleep Apnea and Stroke,

Driving	
Sexual Activity	
Community Support Group reso	urces
Other	
medications, and follow-up appointments/r family physician's office, other community	5 ,
☐ Provide patient with access to resourcest Implementation Resources):	s (also refer to CSBPR Secondary Prevention of Stroke
Recommendations (http://www.strok	very: A survivor's guide to the Canadian Stroke Best Practice rebestpractices.ca/wp- PatientsGuide_F14_EN_July2014-FINAL.pdf)
☐ Post-Stroke Checklist (http://www.stcontent/uploads/2014/06/HSF%20Pedocument	rokebestpractices.ca/wp- ost%20Stroke%20Checklist_WEB.pdf) and appended to this
Disposition	
☐ Admit patient to Emergency Departmen	t
Facility:	Reason:
☐ Admit patient to Inpatient Facility	
Facility: Unit:	Date/Time of transfer:
Reason:	
☐ Refer patient to Stroke Prevention Clinic	or Service
SPC:	
Appointment Date:	Appointment Time:
□Refer patient to Home Care services	
\square Refer patient to outpatient or community	y-based rehabilitation for assessment and treatment
Facility:	
Appointment Date:	Appointment Time:
□ Follow-up with Family Physician:	
Name	
Appointment Date:	Appointment Time:
☐ Send discharge summary/consult letter	to Family Physician within 72 hours
Other Follow-up Appointments:	
□ Name	
	Appointment Time:
□ Name	
Appointment Date:	Appointment Time:

Additional Notes:	

POST-STROKE Checklist &





Developed by the Global Stroke Community Advisory Panel [2012], endorsed by the World Stroke Organization, adapted by the Heart and Stroke Foundation Canadian Stroke Best Practice Recommendations development team [2014]

Patlent Name:		Date Completed:
COMPLETED I	BY: OHEAI	THCARE PROVIDER OPATIENT OFAMILY MEMBER OTHER
SINCE YOUR STROKE OR LA	AST ASSESSI	MENT
1 Secondary Prevention		Refer patient to primary care providers for risk factor
Have you received medical advice on health-related lifestyle changes or medications to	NO (assessment and treatment if appropriate, or secondary stroke prevention services.
prevent another stroke?	YES 🔾	Continue to monitor progress
2 Activities of Daily Living (ADL)	NO ()	Continue to monitor progress
Are you finding it more difficult to take care of yourself?	YES 🔾	Do you have difficulty: Odressing, washing, or bathing? Opreparing hot drinks or meals? Ogetting outside? If Yes to any, consider referral to home care services; appropriate therapist; secondary stroke prevention services.
3 Mobility		
Pioblity	NO O	Continue to monitor progress
Are you finding it more difficult to walk or move safely (i.e., from bed to chair)?	YES 🔘	Are you continuing to receive rehabilitation therapy? No. Consider referral to home care services; appropriate therapist; secondary stroke prevention services. Yes. Update patient record; review at next assessment.
4 Spasticity	NO O	Continue to monitor progress
Do you have increasing stiffness in your arms, hands, or legs?	YES ()	Is this interfering with activities of daily living? No. Update patient record; review at next assessment. Yes. Consider referral to rehabilitation service; secondary stroke prevention services; physician with experience in post-stroke spasticity (e.g., physiatrist, neurologist).
6 Pain	0	
	NO ()	Continue to monitor progress
Do you have any new pain?	YES 🔾	Ensure there is adequate evaluation by a healthcare provider with expertise in pain management.
6 Incontinence	NO ()	Continue to monitor progress
Are you having more problems controlling your bladder or bowels?	YES (Consider referral to healthcare provider with experience in incontinence; secondary stroke prevention services.

SINCE YOUR STROKE OR L	AST ASSESSI	MENT
7 Communication	NO O	Continue to monitor progress
Are you finding it more difficult to communicate?	YES 🔾	Consider referral to speech language pathologist; rehabilitation service; secondary stroke prevention services.
8 Mood	NO (Continue to monitor progress
Do you feel more anxious or depressed?	YES (Consider referral to healthcare provider (e.g., psychologist, neuropsychologist, psychiatrist) with experience in post-stroke mood changes; secondary stroke prevention services.
9 Cognition	NO ()	Continue to monitor progress
Are you finding it more difficult to think, concentrate, or remember things?	YES ()	Is this interfering with your ability to participate in activities? No. Update patient record; review at next assessment. Yes. Consider referral to healthcare provider with experience in post-stroke cognition changes; secondary stroke prevention services; rehabilitation service; memory clinic.
10 Life After Stroke		
9 .	NO (Continue to monitor progress
Are you finding it more difficult to carry out leisure activities, nobbies, work, or engage in sexual activity?	YES ()	Consider referral to stroke support organization (local/provincial support group, Heart and Stroke Foundation of Canada Living with Stroke program); leisure, vocational, or recreational therapist.
Personal Relationships	NO O	Continue to monitor progress
Have your personal relationships (with family, friends, or others) become more difficult or strained?	YES 🔾	 Schedule next primary care visit with patient and family member(s) to discuss difficulties. Consider referral to stroke support organization (local/provincia support group, Heart and Stroke Foundation of Canada); healthcare provider (e.g., psychologist, counsellor, therapist) with experience in family relationships and stroke.
12 Fatigue	NO ()	Continue to monitor progress
Are you experiencing fatigue that is interfering with your ability to do your exercises or other activities?	YES ()	Discuss fatigue with Primary Care provider. Consider referral to home care services for education and counselling.
Other Challenges	NO (Continue to monitor progress
Do you have other challenges or concerns related to your stroke that are interfering with your recovery or causing you distress?	YES ()	 Schedule next primary care visit with patient and family member(s) to discuss challenges and concerns. Consider referral to healthcare provider; stroke support organization (local or provincial support group, Heart and Stroke Foundation of Canada).

For more Information refer to www.heartandstroke.ca or www.strokebestpractices.ca